To evaluate the safety and efficacy of ripertamab and its combination with tacrolimus in the initial treatment of MCD to provide a treatment regimen with higher remission rates, lower recurrence rates, and fewer side effects in patients with MCD.
Age 18-80 years old;
Primary minimal change disease confirmed by renal biopsy (Initial therapy);
24h-UTP>3.5g/d or PCR>3500mg/g, and serum albumin<30g/L;
Agree to participate in the project and sign the informed consent.
Secondary minimal change disease;
eGFR<60 mL/min/1.73m2;
Had history of mental disease, dysnoesia, serious cardiovascular and cerebrovascular diseases, pulmonary insufficiency, malignant tumors or other major diseases that are not suitable for clinical experiments;
Active bleeding in the gastrointestinal tract;
Air Force Military Medical University, China
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Collaborator
Second Affiliated Hospital of Xi'an Jiaotong University
Collaborator
The Second Affiliated Hospital of Air Force Military Medical University
Collaborator
Shaanxi Provincial People's Hospital
Collaborator
Shaanxi Provincial Hospital of Chinese Medicine
Collaborator